We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+0.4%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$549M
AUM Growth
-$96.1M
Cap. Flow
-$15.7M
Cap. Flow %
-2.86%
Top 10 Hldgs %
73.13%
Holding
35
New
2
Increased
2
Reduced
22
Closed
2

Top Buys

Rank Stock Value
1
LITS
Lite Strategy Inc
LITS
+$34.4M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.51M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.01M
4
VSTM icon
Verastem
VSTM
+$1.17M

Top Sells

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$8.73M
2
LHDX
Lucira Health, Inc. Common Stock
LHDX
+$4.39M
3
EPZM
Epizyme, Inc
EPZM
+$2.15M
4
TECX
Tectonic Therapeutic
TECX
+$1.02M
5
CYTK icon
Cytokinetics
CYTK
+$580K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIRM icon
26
Mirum Pharmaceuticals
MIRM
$5.94B
$4.77M 0.87%
298,852
-9,680
-3% -$151K
AXSM icon
27
Axsome Therapeutics
AXSM
$10.4B
$3.91M 0.71%
103,405
-6,750
-6% -$248K
RVMD icon
28
Revolution Medicines
RVMD
$44.6B
$3.68M 0.67%
146,041
-3,959
-3% -$112K
AVDL
29
DELISTED
Avadel Pharmaceuticals
AVDL
$3.03M 0.55%
375,326
-24,674
-6% -$226K
ACAD icon
30
Acadia Pharmaceuticals
ACAD
$5.02B
$2.92M 0.53%
+125,000
New +$2.51M
TECX
31
Tectonic Therapeutic
TECX
$696M
$2.49M 0.45%
53,993
-17,829
-25% -$1.02M
INZY
32
DELISTED
Inozyme Pharma
INZY
$2.06M 0.38%
302,615
-18,109
-6% -$156K
BDTX icon
33
Black Diamond Therapeutics
BDTX
$128M
$1.28M 0.23%
239,888
-8,618
-3% -$60.2K
LHDX
34
DELISTED
Lucira Health, Inc. Common Stock
LHDX
– –
-578,114
Closed -$4.39M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2021 Portfolio in Review

As of Q4 2021, MPM BioImpact held 35 positions worth $549M, down 15% from $645M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

MPM BioImpact's Q4 2021 filing shows 2 new, 2 increased, 22 reduced and 2 closed positions. Its largest new stake was Lite Strategy Inc: 617,549 shares worth $33M. The largest sale was iTeos Therapeutics, an estimated $8.73M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • MPM BioImpact's largest Q4 2021 buy was Lite Strategy Inc: 617,549 shares worth $33M.
  • MPM BioImpact added most to Crinetics Pharmaceuticals in Q4 2021, an estimated $2.01M increase.
  • MPM BioImpact's biggest Q4 2021 reduction was iTeos Therapeutics, cutting an estimated $8.73M.
  • MPM BioImpact fully exited Lucira Health, Inc. Common Stock in Q4 2021, selling an estimated $4.39M.
  • MPM BioImpact's ten largest holdings make up 73% of its $549M portfolio in Q4 2021.
  • MPM BioImpact opened 2 new positions and closed 2 in Q4 2021.
  • MPM BioImpact's portfolio value fell 15% quarter-over-quarter to $549M.

Based on MPM BioImpact's 13F filing for Q4 2021, filed 11 Feb 2022.